Cargando…
The future of cancer immunotherapy: microenvironment-targeting combinations
Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer a...
Autores principales: | Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264181/ https://www.ncbi.nlm.nih.gov/pubmed/32467593 http://dx.doi.org/10.1038/s41422-020-0337-2 |
Ejemplares similares
-
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004) -
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014) -
Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017) -
Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014) -
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
por: Betof Warner, Allison, et al.
Publicado: (2023)